Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07455019) titled 'A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer' on March 3.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The First Affiliated Hospital with Nanjing Medical University
Condition:
Esophageal Cancer
Intervention:
Drug: The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: Ma...